CNS & Neurological Disorders-Drug Targets

Scope & Guideline

Transforming Research into Therapeutic Solutions

Introduction

Welcome to your portal for understanding CNS & Neurological Disorders-Drug Targets, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1871-5273
PublisherBENTHAM SCIENCE PUBL
Support Open AccessNo
CountryUnited Arab Emirates
TypeJournal
Convergefrom 2006 to 2024
AbbreviationCNS NEUROL DISORD-DR / CNS Neurol. Disord.-Drug Targets
Frequency8 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 294, BUSUM 1400 AG, NETHERLANDS

Aims and Scopes

The journal "CNS & Neurological Disorders-Drug Targets" focuses on advancing the understanding and treatment of neurological disorders through innovative drug targets and therapeutic strategies. It encompasses a wide range of topics related to the central nervous system (CNS) and emphasizes the integration of pharmacological, biochemical, and molecular approaches to tackle neurological diseases.
  1. Pharmacological Research:
    The journal emphasizes pharmacological studies on various compounds, including natural products, synthetic drugs, and biologics, aimed at understanding their mechanisms of action in treating neurological disorders.
  2. Neurodegenerative Disorders:
    A significant focus is placed on neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS), exploring novel therapeutic targets and treatment paradigms.
  3. Neuroinflammation and Neuroprotection:
    Research related to neuroinflammation and neuroprotective strategies is a core area, addressing the role of immune responses and potential therapeutic interventions to mitigate neuroinflammatory damage.
  4. Neuropsychiatric Disorders:
    The journal also covers neuropsychiatric conditions, investigating the interplay between neurological and psychiatric symptoms, treatment efficacy, and new pharmacological approaches.
  5. Innovative Drug Delivery Systems:
    There is a keen interest in exploring novel drug delivery systems, including nanotechnology and transdermal systems, to enhance the efficacy of treatments for CNS disorders.
  6. Molecular Mechanisms and Biomarkers:
    The journal promotes research on molecular mechanisms underlying neurological disorders, including the identification of biomarkers for early diagnosis and monitoring of therapeutic responses.
The journal has been adapting to the latest advancements in neuroscience and pharmacology, leading to the emergence of several trending themes that are gaining traction in recent publications. These themes reflect the evolving landscape of neurological research and therapeutic strategies.
  1. Microbiome-Gut-Brain Axis:
    Recent studies have highlighted the significance of the microbiome-gut-brain axis in neurological disorders, indicating a growing interest in how gut health influences brain function and disease progression.
  2. Neuroinflammation as a Therapeutic Target:
    There is an increasing focus on neuroinflammation and its role in various neurological conditions, with research exploring anti-inflammatory strategies as potential therapeutic approaches.
  3. Nanotechnology in Drug Delivery:
    Emerging research on nanotechnology for drug delivery systems is gaining momentum, showcasing innovative methods to enhance the bioavailability and efficacy of treatments for CNS disorders.
  4. Genetic and Epigenetic Research:
    Investigations into genetic and epigenetic factors influencing neurological disorders are on the rise, emphasizing personalized medicine and targeted therapeutic interventions.
  5. Artificial Intelligence and Machine Learning:
    The integration of artificial intelligence and machine learning in analyzing neurological data is becoming a prominent theme, aiding in diagnosis, treatment planning, and outcome prediction.
  6. Phytochemicals and Natural Products:
    There is a renewed interest in the therapeutic potential of phytochemicals and natural products, with research focusing on their mechanisms of action and efficacy in neurological conditions.

Declining or Waning

While the journal continuously evolves with emerging research themes, certain topics have seen a decline in publication frequency or focus. These waning scopes may reflect shifting interests in the field or advancements in alternative therapeutic strategies.
  1. Traditional Herbal Medicine:
    The interest in traditional herbal remedies as standalone treatments has diminished, possibly due to an increasing focus on evidence-based pharmacological approaches and the need for standardized treatment protocols.
  2. Basic Animal Models:
    The reliance on basic animal models for studying neurological diseases appears to be waning, as there is a growing emphasis on more sophisticated models that better replicate human conditions and disease mechanisms.
  3. Single Agent Studies:
    Research focusing solely on the efficacy of single-agent therapies is declining, with a shift towards combination therapies that address the multifactorial nature of neurological disorders.
  4. Epidemiological Studies:
    There seems to be a reduction in the publication of purely epidemiological studies, as the journal increasingly prioritizes studies that integrate clinical findings with molecular and pharmacological research.

Similar Journals

ACS Chemical Neuroscience

Illuminating the Chemical Foundations of Brain Activity.
Publisher: AMER CHEMICAL SOCISSN: 1948-7193Frequency: 12 issues/year

ACS Chemical Neuroscience, published by the American Chemical Society, is a premier journal dedicated to exploring the complex interactions between chemistry and neuroscience. With its ISSN 1948-7193 and a distinguished impact factor that positions it within the top quartiles across multiple categories, including Q1 in Biochemistry, Q2 in Cell Biology, and Q1 in Physiology, this journal serves as an essential platform for researchers engaged in cutting-edge studies from 2010 to 2024. Positioned within the top 15% of its field in Cognitive Neuroscience according to Scopus rankings, ACS Chemical Neuroscience strives to foster interdisciplinary collaboration, publishing significant advancements that integrate chemical concepts with neurological processes. Despite its traditional publication model, the journal is committed to maintaining rigorous peer-review standards and providing valuable insights that drive innovations in therapeutics and understanding the biochemical underpinnings of brain function. Researchers, professionals, and students alike will find in this journal a vital resource for the latest findings and methodologies in the dynamic intersection of chemistry and neuroscience.

DRUG DEVELOPMENT RESEARCH

Pioneering insights in pharmacology and toxicology.
Publisher: WILEYISSN: 0272-4391Frequency: 8 issues/year

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

NEUROLOGICAL RESEARCH

Advancing the Frontiers of Neurological Science
Publisher: TAYLOR & FRANCIS LTDISSN: 0161-6412Frequency: 12 issues/year

NEUROLOGICAL RESEARCH, published by TAYLOR & FRANCIS LTD, is a distinguished journal focusing on the diverse and evolving field of neurology. Established in 1979, this journal has been a prominent platform for disseminating groundbreaking research and clinical advances up to 2024. With an ISSN of 0161-6412 and an E-ISSN of 1743-1328, it offers valuable insights for researchers, professionals, and students interested in the intricate workings of the nervous system. The journal holds a respectable Q2 ranking in the field of Medicine (miscellaneous) and Q3 in the categories of Neurology and Clinical Neurology, reflecting its commitment to high-quality research. Although NEUROLOGICAL RESEARCH does not currently offer an open access option, its contributions to the literature are vital for fostering advancements in neurological understanding and treatment. With an engaged readership and a mission to advance scientific knowledge, NEUROLOGICAL RESEARCH serves as a crucial resource for anyone dedicated to neurological health and innovation.

ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Fostering Global Collaboration in Biochemistry and Biophysics.
Publisher: SCIENCE PRESSISSN: 1672-9145Frequency: 12 issues/year

ACTA BIOCHIMICA ET BIOPHYSICA SINICA, an esteemed journal published by SCIENCE PRESS, is a leading platform in the fields of biochemistry, biophysics, and molecular biology. Based in the United Kingdom, this journal has consistently ranked in the Q2 category for Biochemistry, Biophysics, and Medicine (miscellaneous) in 2023, showcasing its commitment to high-quality research and innovation in life sciences. With a convergence period extending from 1996 to 2024, it features critical insights into biochemical and biophysical processes that underlie biological phenomena. Researchers and professionals seeking to stay at the forefront of discoveries will find its articles to be both informative and transformative. Although not an open-access journal, ACTA BIOCHIMICA ET BIOPHYSICA SINICA aims to advance knowledge and foster collaboration among scientists worldwide, emphasizing its role in the dynamic landscape of biomedical research.

CELLULAR AND MOLECULAR NEUROBIOLOGY

Exploring the Nexus of Cell Biology and Neuroscience.
Publisher: SPRINGER/PLENUM PUBLISHERSISSN: 0272-4340Frequency: 8 issues/year

CELLULAR AND MOLECULAR NEUROBIOLOGY, published by SPRINGER/PLENUM PUBLISHERS, stands as a significant contributor to the fields of cell biology and neuroscience, holding a distinguished position in the academic community with an impact factor that places it in the Q2 category for both Cell Biology and Cellular and Molecular Neuroscience, along with Q1 in Medicine (miscellaneous). Since its inception in 1981, this journal has provided a critical platform for innovative research and thought-provoking reviews, fostering a deeper understanding of complex neurobiological mechanisms. The journal’s rigorous peer-review process ensures the publication of high-quality manuscripts that offer valuable insights into cellular processes and neural functions. With a commitment to advancing knowledge and promoting collaboration among researchers, CELLULAR AND MOLECULAR NEUROBIOLOGY remains an essential resource for professionals and students alike, looking to stay updated on the latest developments in neurobiology.

Drug Target Insights

Advancing the Future of Pharmacology and Drug Discovery.
Publisher: ABOUTSCIENCE SRLISSN: 1177-3928Frequency: 1 issue/year

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.

Letters in Drug Design & Discovery

Transforming Ideas into Breakthroughs in Drug Design
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-1808Frequency: 12 issues/year

Letters in Drug Design & Discovery is an esteemed journal dedicated to advancing the fields of Drug Discovery and Molecular Medicine. Published by Bentham Science Publishers, this journal offers a platform for the dissemination of innovative research and advanced methodologies, enhancing collaboration among researchers and professionals in pharmaceutical sciences. Despite its current Q4 ranking in Drug Discovery and Molecular Medicine and Q3 in Pharmaceutical Science for 2023, the journal is committed to improving its presence in the academic community by providing quality, peer-reviewed publications that cover various aspects of drug design and discovery, including novel therapeutic approaches and methodologies. With a focus on both foundational and cutting-edge research from around the globe, Letters in Drug Design & Discovery is pivotal for those seeking to stay abreast of developments in drug development and molecular research. Researchers are encouraged to submit their work, engage with the burgeoning field, and contribute to the ongoing dialogue driven by this journal, which spans the years from 2005 to 2024. While the journal does not currently offer open access, its contributions remain accessible to a wide range of academic and professional audiences.

Frontiers in Molecular Neuroscience

Exploring the molecular basis of the brain's mysteries.
Publisher: FRONTIERS MEDIA SAISSN: 1662-5099Frequency: 1 issue/year

Frontiers in Molecular Neuroscience, published by FRONTIERS MEDIA SA, is an esteemed open-access journal dedicated to advancing our understanding of the molecular mechanisms underlying neurological functions and disorders. Since its inception in 2008, the journal has established itself as a reputable source of cutting-edge research, earning a respectable Q2 ranking in both the fields of Cellular and Molecular Neuroscience and Molecular Biology as of 2023. With an ongoing commitment to fostering innovation, the journal presents a platform for researchers, professionals, and students to disseminate their findings and engage in scholarly discourse. The E-ISSN 1662-5099 ensures that research is readily accessible, facilitating the exchange of knowledge crucial to tackling the complexities of neurological conditions. Situated in Switzerland, the journal’s global reach is augmented by its open-access model, allowing for wide dissemination of critical research findings to a diverse audience. Join the vibrant community of scientists and practitioners who are shaping the future of molecular neuroscience through their contributions to this dynamic journal.

ACTA NEUROPATHOLOGICA

Innovating Research in Cellular and Molecular Neuroscience
Publisher: SPRINGERISSN: 0001-6322Frequency: 12 issues/year

ACTA NEUROPATHOLOGICA, published by Springer, is a leading journal in the fields of cellular and molecular neuroscience, clinical neurology, and pathology, recognized for its exceptional quality and impactful research. With an impressive impact factor and currently ranked in the Q1 tier across multiple categories in 2023, this journal serves as a premier platform for the dissemination of groundbreaking findings in neuropathology. The journal's robust Scopus rankings highlight its influence, standing at #2 in Pathology and Forensic Medicine and #5 in Clinical Neurology. Since its inception in 1961, ACTA NEUROPATHOLOGICA has provided crucial insights into neurological diseases and disorders, contributing significantly to the advancement of medical science. Aimed at researchers, practitioners, and students alike, this journal fosters a deeper understanding of neurological conditions and encourages innovative approaches within the field. It is essential reading for anyone dedicated to unraveling the complexities of the nervous system.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Elevating Pharmacological Research for Global Impact
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0022-3565Frequency: 12 issues/year

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.